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Abstract In contrast to p53-mediated cell cycle arrest, the
mechanisms of p53-mediated apoptosis in response to cellular
stresses such as DNA damage, hypoxia and oncogenic signals
still remain poorly understood. Elucidating these pathways is all
the more pressing since there is good evidence that the activation
of apoptosis rather than cell cycle arrest is crucial in p53 tumor
suppression. Moreover, the therapeutic interest in p53 as the
molecular target of anticancer intervention rests mainly on its
powerful apoptotic capability. This puzzling elusiveness suggests
that p53 not only engages a plethora of downstream pathways
but itself might possess a biochemical flexibility that goes beyond
its role as a mere transcription factor. Recent evidence of a direct
pro-apoptotic role of p53 protein at mitochondria suggests a
synergistic effect with its transcriptional activation function and
brings an unexpected new level of complexity into p53 apoptotic
pathways. ß 2001 Published by Elsevier Science B.V. on be-
half of the Federation of European Biochemical Societies.
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1. Introduction
In contrast to p53-mediated cell cycle arrest, the mechanism
of p53-mediated apoptosis in response to cellular stresses such
as DNA damage, hypoxia and oncogenic signals remains
poorly understood. The elucidation of this pathway is partic-
ularly important as there is in vivo evidence that it is primarily
the activation of apoptosis by p53 rather than its arrest func-
tion that is crucial in tumor suppression. The importance for
p53-induced apoptosis in tumor suppression is further under-
lined by some human tumor-derived p53 mutants that have a
selective loss-of-function only for apoptosis but not for the
G1 arrest pathway [1]. Moreover, the therapeutic interest in
p53 as the molecular target of anticancer agents lies, of
course, in its apoptotic pathways [2].
2. p53 transcription function and apoptotic target genes
Over the last 5 years, a number of di¡erent p53-induced
genes were proposed to play a role in p53-mediated cell death
including Bax [3], Fas/Apo-1 [4], IGF-BP3 [5], Killer/DR5 [6],
PIGs [7], PAG608 [8], PERP [9], Noxa [10], PIDD [11],
DRAL [12] and p53AIP1 [13] (Fig. 1). Often, these genes
were found in screens that compared a particular tumor cell
line lacking p53 with its counterpart overexpressing ectopic
p53, and some form of subtractive methodology (e.g. subtrac-
tive hybridization, di¡erential display) was used. This was the
case, e.g. for Bax, PIDD and the PIG group. PERP and Noxa
were also found using a subtractive approach but relied on
endogenous p53 by comparing p53+/+ MEFs with their
p533/3 counterparts.
The candidacy of these genes for being p53 apoptosis genes
is based on the following criteria: (i) demonstrating p53-de-
pendency of their induction (usually accompanied by the iden-
ti¢cation of a putative p53-binding site in their 5P-regulatory
region), and (ii) demonstrating that ectopic overexpression of
the candidate gene is su⁄cient to induce apoptosis in p53-
de¢cient tissue culture cells. In some cases (e.g. Noxa and
PIDD), downregulation of the endogenous gene by antisense
methods decreases (but never abolishes) cell death rate after
stress.
However, most known p53 target genes are induced to sim-
ilar levels during p53-mediated G1 arrest and apoptosis [9].
This strongly suggests that they function more generally in
transducing p53 stress signals, but that they are not the deci-
sive death determinant in the cell’s decision fork whether to
arrest or to undergo cell death. This situation holds true for
the p53 target genes Bax, IGF-BP3, Killer/DR5, the PIGs,
PIDD, and Noxa. Each of these genes is similarly induced
in doxorubicin-stressed p53+/+ MEFs, which only arrest,
and in doxorubicin-stressed E1A p53+/+ MEFs, which only
apoptose [9]. Notable exceptions in apoptosis speci¢city is
PERP and possibly, p53AIP1. PERP, a member of the tetra-
span transmembrane protein family PMP22/gas3, was cloned
after subtracting against G1 arrest-associated p53-induced
messages. PERP is speci¢cally induced during p53-mediated
apoptosis in E1A-harboring MEF cells but not during G1
arrest [9]. Also, stress-mediated serine 46 phosphorylation
on p53 is speci¢cally associated with induction of p53AIP1
but not with induction of p21Waf1, Noxa and PIG3, suggest-
ing that p53AIP1 might be an apoptosis gene induced by this
particular modi¢cation of p53 [13]. The induction of candi-
date apoptosis genes exhibit variable kinetics with some being
rather slow in their inductive response (24 h or longer), e.g.
PIG3 and p53AIP1. While many of the above-mentioned can-
didates are widely expressed, DRAL is an example of a tissue-
restricted response gene which is exclusively expressed in car-
diomyocytes [12].
The ultimate proof for any p53 apoptosis candidate gene
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would be a loss-of-function knock out mouse (KO) for that
candidate which shows resistance to a p53-dependent apopto-
tic stress stimulus. This would de¢nitively demonstrate that
speci¢c gene’s requirement for p53-mediated apoptosis. So
far, of all candidates only the Bax and APO-1 KO mice
have been made, but the available results fail to demonstrate
such a requirement. Bax requirement is, at best, partial and
context-dependent. Bax de¢ciency only attenuates but does
not abrogate the p53-dependent apoptotic pathway in E1A-
expressing primary mouse embryo ¢broblasts [14] and in cho-
roid plexus tumors of transgenic T-antigen-expressing mice
[15]. On the other hand, Bax-de¢cient thymocytes are fully
competent for Q-irradiation (IR)-induced p53-dependent apo-
ptosis [16,17]. Furthermore, the mouse Bax gene lacks a p53-
binding site (although the human Bax promoter has a con-
sensus binding site), indicating poor evolutionary conserva-
tion. Moreover, human p53 delta Pro, which lacks the pro-
line-rich region 61^94, induces Bax normally but has lost its
apoptotic function [18]. Likewise, APO-1 is fully dispensable
for Q-IR induced p53-dependent apoptosis as shown by spon-
taneously Fas-de¢cient mice (so-called lpr mice) [17,19].
Taken together, despite many years of intense search for the
critical p53 apoptosis e¡ector(s), we are still faced with a
vexing elusiveness of a clear understanding of how p53 does
the job of inducing cell death. It strongly argues that this
powerful protein simultaneously engages in a multitude of
downstream pathways to mediate cell death. In apoptosis,
p53 does not sit on top of a simple ‘monorail’ transcriptional
pathway, as it does in p53-mediated G1 and G2 arrest. In-
stead, p53 enlists a spectrum of di¡erent biological e¡ector
pathways. It even opens up the possibility that this molecule
has pleiotropic biochemical functions, a sort of jack of more
than one trade. This might require biochemical £exibility for
functioning in transcriptional activation and transcription-in-
dependent modes of action, which in turn might be cell type-
and damage-speci¢c. What is the evidence for such transcrip-
tion-independent modes of action of p53-mediated apopto-
sis?
3. Transrepression
A transrepression mechanism was suggested which involves
selective targeting by wild-type but not mutant p53 protein of
the corepressor mSin3a, coupled with histone deacetylase, to
the regulatory regions of the microtubule-associated protein 4.
Map4, a p53-repressed gene, has been correlated with a delay
in apoptosis [20]. In contrast to the non-speci¢c repression
previously observed in some transient reporter assays when
greatly overexpressed p53 and target promoters were used,
Map4 repression appears to be speci¢c. However, the precise
DNA-binding domain and the exact role of Map4 in apopto-
sis remain to be identi¢ed.
4. Transcription-independent pathways of p53 apoptosis
Evidence for transcription-independent pathways for p53-
mediated apoptosis has been accumulating for years. In some
cell types, p53-dependent apoptosis occurs in the absence of
any gene transcription or protein synthesis [21^23]. Further-
more, inhibitors of protein phosphatases induce p53-depen-
dent apoptosis in the absence of transcriptional activation
[24]. Moreover, the transcriptionally inactive p53 mutants
del(1^214) and p53gln22; ser23, which fail to speci¢cally bind to
DNA or act as transcription factor of Waf1 and other target
genes, act as potent inducers of apoptosis in several cell sys-
tems [25^27]. Interestingly, p53 protein from cell-free postnu-
clear extracts (which contain mitochondria), made from trans-
formed ¢broblasts that undergo p53-dependent apoptosis
after Q-IR, directly mediates the activation of e¡ector cas-
pases. Immunodepletion of p53 protein from these extracts
blocks this activity, suggesting direct protein^protein signaling
from p53 to the Casp9/Casp3 activation cascade. This path-
way requires caspase 8 [28].
5. Mitochondria, protein translocation and apoptosis
Mitochondria are central integrators and transducers for
Fig. 1. Transcriptionally dependent and independent mechanisms of p53-mediated apoptosis both activate the mitochondrial pathway of cell
death. Alterations in mitochondrial membrane potential, mitochondrial ROS production and/or cytochrome c release can result from p53-medi-
ated transcriptional activation of mitochondrial proteins such as Noxa, p53 AIP1 and Bax. Moreover, the rapid translocation of p53 protein di-
rectly to mitochondria occurs in a broad spectrum of cell types and death signals and enhances the apoptotic potency of p53. In addition, p53
can enlist a multitude of other p53-induced e¡ector genes. p53 can activate the death receptor pathway via death receptor target genes (DR-5,
Apo-1) or death-domain-containing proteins (PIDD). Other target genes operate through unknown apoptotic pathways (PIGs, DRAL,
PAG608, PERP).
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pro-apoptotic signals, forming the nexus between the non-spe-
ci¢c inducer phase and the ¢nal execution phase of apoptosis.
This is particularly but not exclusively the case with those
inducers of cell death that activate apoptosis independently
of death receptor pathways on the cell surface. Such inducers
include cell damage from Q-IR, anticancer drugs, hypoxia and
growth factor withdrawal. A major reason for the central role
of mitochondria is that these organelles store a host of critical
apoptotic activators and e¡ectors of cell death in their inter-
membranous space. These include cytochrome c (see e.g. [29]),
Smac/Diablo (a cytochrome c-dependent caspase co-activator)
[30,31], apoptosis inducing factor (AIF), a £avoprotein which
activates nuclear endonucleases [32] and procaspases 2, 3 and
9 (reviewed in [33]). Permeabilization of the outer mitochon-
drial membrane, which is associated with mitochondrial dys-
function and collapse of the inner membrane gradient vBM,
causes the release of these pro-apoptogenic factors. This re-
lease constitutes the point of no return and triggers the exe-
cution phase of cell suicide because it directly activates the
latent apoptotic machinery.
One striking feature of apoptosis signaling is protein trans-
location of signal and e¡ector molecules between three major
cellular compartments. This includes translocation to and
from mitochondria, the cytoplasm and the nucleus. Of partic-
ular interest are a growing list of pro-apoptotic proteins that
undergo translocation to mitochondria, where they exert their
pro-apoptotic functions by inducing organellar dysfunction.
The classic pro-apoptotic bcl family members Bax [34,35],
Bad (reviewed in [33]), Bim [36] and truncated tBid [37,38]
do this by increasing mitochondrial permeability which,
among others, leads to the release of cytochrome c. For ex-
ample, inactive cytosolic Bid undergoes N-terminal cleavage
by caspase 8 to tBid, leading to a newly exposed glycine res-
idue which now becomes the target of posttranslational N-
myristoylation [39]. This modi¢cation promotes its mitochon-
drial targeting and pro-apoptotic e¡ect. Moreover, ionizing
IR induces translocation of the stress kinase SAPK/JNK to
mitochondria which in turn causes phosphorylation and inac-
tivation of anti-apoptotic Bcl-xL [40]. Similarly, phorbol es-
ters induce translocation of protein kinase C delta to mito-
chondria, altering a yet unknown substrate [41]. The evolving
theme here is that these mitochondrially translocating proteins
belong to unrelated biochemical classes of molecules, most of
which were previously not associated with mitochondrial
functions. Most unexpectedly, this diversity is now even ex-
tending to transcription factors.
6. p53 and mitochondria
We recently showed that a fraction of stress-induced endog-
enous p53 protein targets to mitochondria in response to var-
ious types of damage in human and mouse, malignant and
non-malignant cell lines [42]. This result was obtained using
all methods available for determination of subcellular local-
ization, including carefully controlled subcellular fractiona-
tion. p53 translocation strictly occurs at the onset of p53-de-
pendent apoptosis, but not during p53-independent apoptosis
triggered e.g. by the death receptor pathway, nor does it occur
during p53-mediated cell cycle arrest. The translocation of p53
to mitochondria is rapid (within 1 h after cell damage) and
precedes changes in mitochondrial membrane potential, cyto-
chrome c release and procaspase-3 activation [42].
Mitochondrial localization of endogenous p53 can be visu-
alized by in situ immuno£uorescence of whole cells after 5^6 h
of hypoxic stress [43]. Immuno-£ow cytometry analysis of
isolated mitochondria show that a signi¢cant amount of mi-
tochondrial p53 localizes to the membranous compartment.
This result was con¢rmed by direct localization of p53 via
immuno-electronmicroscopy of stressed mitochondria, while
untreated mitochondria failed to give a signal. Further sub-
organellar localization of p53 by limited trypsin digestion sug-
gests that a signi¢cant amount of mitochondrial p53 is located
at the surface of the organelle, while a subfraction appears to
be intraorganellar (trypsin-resistant) [42]. Mitochondrial asso-
ciation of p53 and its signi¢cant surface localization can be
reproduced in vitro in an organellar pull-down assay with
puri¢ed baculoviral p53 added to isolated mitochondria. Con-
trol recombinant PCNA protein fails to associate. Co-immu-
noprecipitation from stressed whole cells or mitochondria
shows that mitochondrial p53 is found in an in vivo complex
with the mitochondrial import motor mt hsp70. This p53 sub-
population possibly corresponds to the trypsin-resistant sub-
fraction [42]. A similar in vivo complex between mt hsp70
(also called mot-2) and p53 was independently observed in
NIH 3T3 cells [44]. Interestingly, forced overexpression of
ectopic mot-2 abolished the transcriptional ability of p53 in
reporter assays and nuclear translocation, suggesting that p53
can be completely siphoned o¡ into mitochondria [44].
Similar results were seen in clean ectopic systems in the
absence of additional DNA damage. In p53-de¢cient EB1
cells which harbor a stable, inducible wild-type p53 transgene,
mitochondrial p53 accumulation occurs concomitantly with
nuclear p53 accumulation and precedes the onset of apoptosis
after sole induction of ectopic p53 [42]. On the other hand,
mitochondrial regulators of apoptosis in£uence the induction
of mitochondrial p53 accumulation. Overexpression of anti-
apoptotic Bcl-2 or Bcl-xL abrogates stress-signal-mediated mi-
tochondrial p53 accumulation and apoptosis. In contrast, Bcl-
2 or Bcl-xL overexpression does not abrogate total cellular
p53 accumulation nor the ability to undergo stress-induced
cell cycle arrest [42].
Importantly, nuclear bypass experiments demonstrate that
mitochondrial p53 localization is su⁄cient for launching p53-
dependent apoptosis from the level of mitochondria. Deliber-
ate targeting of ectopic p53 to mitochondria (via fusions with
mitochondrial import leader peptide, designated L-p53) by-
passes the nucleus and is su⁄cient to induce apoptosis in three
di¡erent p53-de¢cient tumor cell lines (Saos-2, H1299 and
HeLa) ([42] and unpublished observation). Interestingly, a mi-
tochondrially targeted but truncated p53 protein (L-p53 1^
305), which misses the entire C-terminus, has a higher apo-
ptotic activity than L-wtp53, suggesting that the C-terminus
containing the tetramerization domain is dispensable for mi-
tochondrial action. This is in contrast to the nuclear action of
p53, which requires the C-terminus for tetramerization in or-
der to optimally function as a transcription factor. Finally, the
mitochondrial p53 action is transcription-independent since
targeted mutant L-p53 R175H, which is completely inactive
as transcription factor, retains its apoptotic activity as a mi-
tochondrial protein [42].
Based on these results, we propose a model in which p53
can contribute to cell death by rapid direct signaling at the
mitochondria. This pathway likely acts in synergy with the
transcription-dependent mode of p53, thereby amplifying the
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apoptotic potency and speed of p53. Moreover, based on its
implication in a broad spectrum of cell types and death sig-
nals, this enhancer pathway has the potential for being ge-
neric, accompanying the action of most or all p53-induced
apoptotic genes (Fig. 1). Important questions for the future
are: which are the protein(s) that mitochondrial p53 is talking
to and what secondary apoptotic regulators are being acti-
vated as a result of this.
In a general sense, what do we currently know about p53
death signaling via mitochondria? Downstream of mitochon-
dria, p53-dependent apoptosis clearly goes through caspase
activation involving the caspase-9/Apaf-1 apoptosome, since
loss of both factors substitute for loss of p53 and cause resis-
tance to Myc-induced apoptosis of mouse embryo ¢broblasts
[45]. At the mitochondrial level, however, the exact nature of
p53-induced alterations are unclear. Several independent
apoptogenic events have been described. Using adenoviral
transduction of wtp53 into HeLa cells (functionally null for
p53), Li et al. found that p53 signaling generates production
of reactive oxygen species (ROS), which in turn causes col-
lapse of the mitochondrial membrane potential vBM. Of note,
this group found no evidence of mitochondrial cytochrome c
release nor Bax translocation (despite Bax induction) or Bid
cleavage [46]. In contrast, using similar adenoviral transduc-
tion of wtp53 into Saos-2 cells (null for p53), Schuler et al.
[47] found that the p53-transduced cytosolic extracts con-
tained a cytochrome c-releasing activity that was not p53 itself
but was dependent on the presence of cytosolic Bax. These
varying results from two similar experimental systems will
require more clari¢cation.
Aside from Bax, the p53-induced gene products Noxa and
p53AIP1 are also mitochondrial proteins and probably gen-
erate their own set of mitochondrial dysfunctions, at least in
some circumstances. Bax and Noxa are BH3-domain-contain-
ing proteins, while p53 AIP1 has no signi¢cant homology to
any protein in the public database. However, the onset of
mitochondrial dysfunction by these genes might be delayed,
since their transcription and translation requires time. This
notion is in line with the fact that p53AIP1 mRNA induction
was slow and only seen 24 h after Q-IR [13].
Does mitochondrial accumulation of p53 represent a prece-
dent for other transcription factors implicated in apoptosis?
The answer is yes. The nuclear orphan steroid receptor TR3
(also called Nur77 or NGFIB), a member of the steroid/thy-
roid receptor superfamily is a bona ¢de transcription factor
with a zinc ¢nger DNA-binding domain £anked by transacti-
vation domains and a binding domain for an as yet unknown
ligand. TR3 is induced and acts as a transcription factor in
response to epidermal growth factor and all-trans-retinoic
acid. On the other hand, TR3 mediates apoptosis in di¡erent
cell types in vivo, e.g. in neurons, autoreactive developing T
cells and human cancer cells ([48] and references within). TR3
is upregulated by apoptotic stimuli like seizures, neuronal is-
chemia and ligation of the T cell receptor. Unexpectedly,
when TR3 works as an apoptotic factor, its transcriptional
activation function is turned o¡ [48]. Instead, in response to
a wide variety of apoptotic stimuli, TR3 relocates from the
nucleus to the surface of mitochondria, where it triggers mem-
brane permeability, cytochrome c release and apoptotic cell
death. The TR3 DNA-binding domain, required for transcrip-
tional activity, is not required for mitochondrial targeting. As
is true for mitochondrial p53, mitochondrial TR3 is also suf-
¢cient to cause cell death. Moreover, as for mitochondrial
p53, its action is blocked by bcl-2 [48]. Thus, there are now
two nuclear transcription factors that, by virtue of their sub-
cellular relocalization, are capable of mediating lethal signal-
ing directly through mitochondria. For one thing, these two
examples add another level of complexity to the regulation of
apoptosis. However, their greater signi¢cance might lie in the
fact that it forces us to rethink our neat biochemical classi¢-
cation scheme of one protein ^ one mode of action.
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